-
Product Insights
New![]()
Net Present Value Model: Otsuka Holdings Co Ltd’s Centanafadine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Otsuka Holdings Co Ltd’s (Deudextromethorphan hydrobromide + Quinidine sulfate)
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Otsuka Holdings Co Ltd's (Deudextromethorphan hydrobromide + Quinidine sulfate) Drug Details: AVP-786 is under development for the treatment of agitation associated with dementia of...
-
Company Profile
![]()
Otsuka Holdings Co Ltd – Company Profile
Otsuka Holdings Co Ltd (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions, and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals,...
Add to Basket -
Company Profile
![]()
Otsuka Corp – Company Profile
Otsuka Corp (Otsuka) is a provider of system integration services and related support services. The company provides computers, communications equipment, LED lighting products, smart devices and copiers. It also provides optimized system services from consulting to design and development of system, installation work and transportation, construction of networks, distributing supplies, hardware and software maintenance, telephone support and outsourcing to support the installed systems and business operations. It serves a wide diversity of corporate customers engaged in a variety of business...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Processa Pharmaceuticals Inc’s Roducitabine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Peripheral Vascular Stents – Otsuka Holdings Co Ltd – BIOMIMICS 3D
GlobalData, the industry analysis specialist, has released its latest report: Peripheral Vascular Stents - Otsuka Holdings Co Ltd - BIOMIMICS 3D. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also...
-
Product Insights
Otsuka Medical Devices Co Ltd Pipeline Insight and Competitive Landscape, 2023
Otsuka Medical Devices Co Ltd (Otsuka Medical Devices), a subsidiary of Otsuka Holdings Co Ltd, is a medical device manufacturing company. The company concentrates on revolutionary diagnostic and treatment technologies that find solutions in treating drug-refractory patients and intractable diseases. Its products include endoscopy, orthopedic implants, granulocyte apheresis columns, vascular intervention devices and regenerative medical devices. Otsuka Medical Device provides its products through its distributors located across Asia region. The company has its operations in Minato-ku and Tokyo, Japan. Otsuka...
-
Product Insights
NewPolycystic Kidney Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Polycystic Kidney Disease Clinical Trials Market Report Overview The polycystic kidney disease clinical trial market research report provides an overview of the polycystic kidney disease clinical trials scenario. The report provides top-line data relating to the clinical trials on polycystic kidney disease. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
NewAutism Spectrum Disorder (ASD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Autism Spectrum Disorder (ASD) Clinical Trials Market Report Overview The Autism Spectrum Disorder (ASD) clinical trial market research report provides an overview of the Autism Spectrum Disorder (ASD) clinical trials scenario. This report provides top-line data relating to the clinical trials on ASD and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NO-13065 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NO-13065 in Obesity Drug Details: NO-13065 is under development for the treatment of obesity....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rebamipide SR in Gastritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rebamipide SR in GastritisDrug Details:Rebamipide SR is under development for the treatment of acute and chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tesidolumab in Posterior Uveitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tesidolumab in Posterior Uveitis Drug Details: Tesidolumab (LFG-316) is under development for the treatment of...
-
Track & Monitor
New![]()
Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YL-202 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.YL-202 in Non-Small Cell Lung Cancer Drug Details:YL-202 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LPCN-1154 in Post Partum Depression (Maternal Depression / Postnatal Depression)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Post Partum Depression (Maternal Depression / Postnatal Depression) Drug Details: Brexanolone is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7200394 in Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RO-7200394 in Macular EdemaDrug Details:RO-7200394 is under development for the treatment of macular edema secondary to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OPS-2071 in Irritable Bowel Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OPS-2071 in Irritable Bowel Syndrome Drug Details: OPS-2071 is under development for diarrhea-predominant irritable bowel syndrome of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Centanafadine Sr in Attention Deficit Hyperactivity Disorder (ADHD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Centanafadine Sr in Attention Deficit Hyperactivity Disorder (ADHD) Drug Details:Centanafadine SR (EB-1020) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Centanafadine Sr in Major Depressive Disorder
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Centanafadine Sr in Major Depressive Disorder Drug Details:Centanafadine SR (EB-1020) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OPB-111077 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.OPB-111077 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)Drug Details:OPB-111077 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.